Abstract: The present invention relates to processes for converting clarithromycin Form 0 to clarithromycin Form II, which include slurrying clarithromycin the Form 0 in water. The present invention also relates to processes for the preparation of clarithromycin Form II by converting erythromycin A to clarithromycin and thereafter converting clarithromycin Form 0 to clarithromycin Form II by slurrying. The present invention further relates to the novel clarithromycin polymorph Form IV, a process for its preparation, pharmaceutical compositions comprising the compound, and methods of using the compound as a therapeutic agent.

Abstract: The present invention relates to processes for converting clarithromycin Form I to clarithromycin Form II, which include slurrying clarithromycin the Form I in water. The present invention also relates to processes for the preparation of clarithromycin Form II by converting erythromycin A to clarithromycin and thereafter converting clarithromycin Form I to clarithromycin Form II by slurrying.

Abstract: The present invention relates to processes for converting clarithromycin Form 0 to clarithromycin Form II, which include slurrying clarithromycin the Form 0 in water. The present invention also relates to processes for the preparation of clarithromycin Form II by converting erythromycin A to clarithromycin and thereafter converting clarithromycin Form 0 to clarithromycin Form II by slurrying. The present invention further relates to the novel clarithromycin polymorph Form IV, a process for its preparation, pharmaceutical compositions comprising the compound, and methods of using the compound as a therapeutic agent.

Abstract: The present invention provides a process for preparing crystalline lorazepam substantially free of bound solvent from a lorazepam alcohol solvate or hydrate by suspending the lorazepam solvate in an organic medium selected from ethyl acetate, cyclohexane, dichloromethane, toluene and mixtures thereof. This process is useful in producing the anti-anxiety and sedative agent lorazepam in increased yields. A process for converting lorazepam lower alcohol solvates to lorazepam hydrate is also disclosed.

Abstract: The present invention provides a process for preparing crystalline lorazepam substantially free of bound solvent from a lorazepam alcohol solvate or hydrate by suspending the lorazepam solvate in an organic medium selected from ethyl acetate, cyclohexane, dichloromethane, toluene and mixtures thereof. This process is useful in producing the anti-anxiety and sedative agent lorazepam in increased yields. A process for converting lorazepam lower alcohol solvates to lorazepam hydrate is also disclosed.

Abstract: The present invention relates to processes for preparing protected silylated clarithromycin oxime, preferably 6-O-methyl-2′, 4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime (“S-MOP oxime”), and for converting protected silylated clarithromycin oxime, preferably S-MOP oxime, to clarithromycin. Processes for preparing protected silylated clarithromycin oxime according to the present invention, include reacting a silyl oxime derivative with methylating agent in the presence of at least one solvent and a base, where the solvent comprises methyl tertbutyl ether.

Abstract: Food products are processed prior to consumption in a press form, comprising two hinged together trays, rows of multiple separate food product molding apertures arranged staggered relative to one another in the trays, feet members mounted for support of and underneath the trays, respectively arranged in alignment with and adjacent to a molding aperture, said feet members being utilized to intercept and eject food products from the molding apertures, when the trays are swung inwardly from an aligned into a superposed position.

Abstract: An improved apparatus for making dough envelopes containing filling. The apparatus is molded from plastic and includes a frame structure having a plurality of interconnected hexagonal molds so as to form a honeycomb type structure. Each hexagonal mold includes six inclined cutting edges which are connected around a central inverted conical chamber. The inverted conical chamber partially supports the dough envelope during formation to produce uniformly shaped and aesthetically pleasing envelopes. Further, horizontal pasting faces are provided in the corners of each mold between the conical chamber base and cutting edges lower edges. These horizontal pasting faces in combination with the cutting edges provide a strong and uniform seal around the dough envelope edges.

Abstract: Food products are processed prior to consumption in a press form having multiple, separate, pre-selected planar food product molds, each having tapered walls, providing easy food product removal. The food products can have pastry dough exteriors and can be filled with selected food fillings held in position and shaped by dough crust exteriors. Multiple press form food product molds have regular planar shapes disposed multiple in a tray. One face of each product mold has a cutting-edge knife disposed thereon, conforming to the mold interior shape. The cutting-edge knife can be disposed at either mold wall taper terminus. A cooperatively shaped, one-piece negative pusher plug mold, sized to intercept each one of the multiple food product molds disposed in the tray, is used to cooperatively push each food product out of the molds in the tray simultaneously.